Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Eric L. Ross(McLean Hospital), Steven E. Arnold(University of Pennsylvania)
Cited by 128
Related Papers
Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia
|Journal of Clinical Investigation|2004|412
Caspase-3 Is Enriched in Postsynaptic Densities and Increased in Alzheimer's Disease
|American Journal Of Pathology|2008|205
Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer’s disease
|Scientific Reports|2024|52